An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...

Findings support model in which accelerated biological aging of mammary epithelia may underpin breast cancer susceptibility ...

PanGIA Biotech, Inc. ("PanGIA Biotech" or "Company") announced that two research abstracts have been accepted for presentation at the American Association for Cancer Research ("AACR") Annual Meeting ...

Prostate cancer remains one of the most common diseases among men, yet current screening methods often lead to unnecessary ...

TOBY’s urine-based MCED test received FDA Breakthrough Device Designation. This is the first urine-based MCED platform ...

A new liquid biopsy test using artificial intelligence models could help spot a rare type of bone and soft tissue cancer that ...

Artificial intelligence (AI) could help physicians determine if survivors of childhood cancer need extra support - and the more information included in AI prompting, the better its performance. This ...

New cfDNA test enables multicancer detection with high accuracy, offering a cost effective approach for early diagnosis and ...

TOBY, Inc., a biotechnology company developing non-invasive cancer screening technologies, today announced that the U.S. Food ...

This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.